MX2015009323A - Composicion que comprende un antagomir encapsulado. - Google Patents
Composicion que comprende un antagomir encapsulado.Info
- Publication number
- MX2015009323A MX2015009323A MX2015009323A MX2015009323A MX2015009323A MX 2015009323 A MX2015009323 A MX 2015009323A MX 2015009323 A MX2015009323 A MX 2015009323A MX 2015009323 A MX2015009323 A MX 2015009323A MX 2015009323 A MX2015009323 A MX 2015009323A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- inhibitor
- relates
- cardiac disorders
- encapsulated antagomir
- Prior art date
Links
- 208000020446 Cardiac disease Diseases 0.000 abstract 2
- 208000019622 heart disease Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 108091070501 miRNA Proteins 0.000 abstract 1
- 239000002679 microRNA Substances 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13305082.3A EP2759595B1 (en) | 2013-01-24 | 2013-01-24 | Composition comprising an encapsulated antagomir |
| PCT/IB2014/058500 WO2014115103A1 (en) | 2013-01-24 | 2014-01-23 | Composition comprising an encapsulated antagomir |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015009323A true MX2015009323A (es) | 2016-04-04 |
Family
ID=47683670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015009323A MX2015009323A (es) | 2013-01-24 | 2014-01-23 | Composicion que comprende un antagomir encapsulado. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150352055A1 (enExample) |
| EP (2) | EP2759595B1 (enExample) |
| JP (1) | JP2016506923A (enExample) |
| KR (1) | KR20160018451A (enExample) |
| CN (1) | CN105229151A (enExample) |
| AU (1) | AU2014208419A1 (enExample) |
| BR (1) | BR112015017650A2 (enExample) |
| CA (1) | CA2898958A1 (enExample) |
| ES (2) | ES2606636T3 (enExample) |
| HK (1) | HK1219753A1 (enExample) |
| HU (1) | HUE032125T2 (enExample) |
| MX (1) | MX2015009323A (enExample) |
| PL (1) | PL2759595T3 (enExample) |
| RU (1) | RU2668794C2 (enExample) |
| WO (1) | WO2014115103A1 (enExample) |
| ZA (1) | ZA201505602B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6208228B2 (ja) | 2012-06-21 | 2017-10-04 | ミラゲン セラピューティクス， インコーポレイテッド | ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤 |
| EP3247716A4 (en) * | 2015-01-20 | 2018-10-17 | Miragen Therapeutics, Inc. | Mir-92 inhibitors and uses thereof |
| WO2018183127A1 (en) * | 2017-03-25 | 2018-10-04 | MiRagen Therapeutics, Inc. | Mir-92 inhibitors for treatment of heart failure |
| CN113490488A (zh) * | 2019-03-14 | 2021-10-08 | M技术株式会社 | Plga微粒子、其缓释制剂以及其制造方法 |
| CN110484537B (zh) * | 2019-09-02 | 2021-07-27 | 中国水产科学研究院淡水渔业研究中心 | 一种miR-92促进剂及其注射剂的制备方法和应用 |
| CN110804659B (zh) * | 2019-10-23 | 2023-02-03 | 华南农业大学 | 一种血清外泌体ssc-miR-92b-3p作为母猪早期妊娠诊断分子标志物的应用 |
| CN110917359A (zh) * | 2019-11-21 | 2020-03-27 | 武汉理工大学 | 离子键自组装制备PEG-P（Asp-AP）-ANTAGOMIR-RNA微球 |
| WO2021251526A1 (ko) * | 2020-06-11 | 2021-12-16 | 주식회사 프로스테믹스 | 신규한 mirna 유사체 및 이의 용도 |
| CN111729088B (zh) * | 2020-08-21 | 2020-12-15 | 江苏申基生物科技有限公司 | 一种微小核糖核酸miR-34a偶联探针及其制备方法 |
| WO2025050037A1 (en) * | 2023-08-31 | 2025-03-06 | The Regents Of The University Of Colorado, A Body Corporate | Microrna-15b antagomir and cerium oxide nanoparticles, and uses of same for treatment of intrauterine growth restriction |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8383158B2 (en) * | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
| EP1648914A4 (en) * | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| US8288356B2 (en) * | 2007-10-04 | 2012-10-16 | Santaris Pharma A/S | MicroRNAs |
| DE102007052114B4 (de) * | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
| GB0814302D0 (en) * | 2008-08-05 | 2008-10-01 | Coretherapix Slu | Compounds and methods |
| CA2763156A1 (en) * | 2009-05-20 | 2010-11-25 | Board Of Regents, The University Of Texas System | Identification of micro-rnas involved in post-myocardial infarction remodeling and heart failure |
-
2013
- 2013-01-24 EP EP13305082.3A patent/EP2759595B1/en not_active Not-in-force
- 2013-01-24 ES ES13305082.3T patent/ES2606636T3/es active Active
- 2013-01-24 PL PL13305082T patent/PL2759595T3/pl unknown
- 2013-01-24 HU HUE13305082A patent/HUE032125T2/en unknown
-
2014
- 2014-01-23 AU AU2014208419A patent/AU2014208419A1/en not_active Abandoned
- 2014-01-23 CA CA2898958A patent/CA2898958A1/en not_active Abandoned
- 2014-01-23 RU RU2015134770A patent/RU2668794C2/ru not_active IP Right Cessation
- 2014-01-23 ES ES14706098.2T patent/ES2688160T3/es active Active
- 2014-01-23 EP EP14706098.2A patent/EP2948551B1/en not_active Not-in-force
- 2014-01-23 KR KR1020157022914A patent/KR20160018451A/ko not_active Withdrawn
- 2014-01-23 CN CN201480017728.3A patent/CN105229151A/zh active Pending
- 2014-01-23 HK HK16107653.5A patent/HK1219753A1/zh unknown
- 2014-01-23 WO PCT/IB2014/058500 patent/WO2014115103A1/en not_active Ceased
- 2014-01-23 MX MX2015009323A patent/MX2015009323A/es unknown
- 2014-01-23 BR BR112015017650A patent/BR112015017650A2/pt not_active IP Right Cessation
- 2014-01-23 US US14/763,181 patent/US20150352055A1/en not_active Abandoned
- 2014-01-23 JP JP2015554285A patent/JP2016506923A/ja active Pending
-
2015
- 2015-08-04 ZA ZA2015/05602A patent/ZA201505602B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2759595T3 (pl) | 2017-09-29 |
| ES2606636T3 (es) | 2017-03-24 |
| KR20160018451A (ko) | 2016-02-17 |
| EP2948551A1 (en) | 2015-12-02 |
| CN105229151A (zh) | 2016-01-06 |
| BR112015017650A2 (pt) | 2017-11-21 |
| HK1219753A1 (zh) | 2017-04-13 |
| ZA201505602B (en) | 2017-05-31 |
| EP2759595A1 (en) | 2014-07-30 |
| WO2014115103A1 (en) | 2014-07-31 |
| US20150352055A1 (en) | 2015-12-10 |
| HUE032125T2 (en) | 2017-08-28 |
| JP2016506923A (ja) | 2016-03-07 |
| RU2015134770A (ru) | 2017-03-03 |
| RU2668794C2 (ru) | 2018-10-02 |
| EP2759595B1 (en) | 2016-09-14 |
| ES2688160T3 (es) | 2018-10-31 |
| AU2014208419A1 (en) | 2015-08-13 |
| EP2948551B1 (en) | 2018-05-02 |
| CA2898958A1 (en) | 2014-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015009323A (es) | Composicion que comprende un antagomir encapsulado. | |
| HK1226063A1 (zh) | 选择性grp94抑制剂和其用途 | |
| EP3068289A4 (en) | Prevention and treatment of bed exits, falls, and other conditions | |
| WO2015073587A3 (en) | Synthetic membrane-receiver complexes | |
| SG10201809290SA (en) | Compositions and Methods to Treating Hemoglobinopathies | |
| ZA201504458B (en) | Treatment compositions comprising microcapsules, primary or secondary amines, and formaldehyde scavengers | |
| CL2015002710A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso. | |
| UY34811A (es) | Compuestos y composiciones para inhibir la actividad de la abl1, abl2 y bcr-abl1 | |
| HK1220980A1 (zh) | 用於治疗庞贝氏症的方法和组合物 | |
| MX2015009037A (es) | Enjuague nasal con miel. | |
| SG11201604821YA (en) | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith | |
| MX2016005760A (es) | Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| GB2535876A (en) | Absorbent clumping animal litter compositions | |
| MX2016003823A (es) | Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma. | |
| IL244182B (en) | Preparations, methods and systems for the treatment of skin disorders | |
| PL3065732T3 (pl) | Związki, kompozycje i odpowiednie zastosowania do zapobiegania i/lub leczenia dyslipidemii | |
| MX2012013078A (es) | Composiciones antimicrobianas liquidas de baja formacion de espuma, modificadas reologicamente, y sus metodos de uso. | |
| WO2015002971A3 (en) | Modulators of growth hormone receptor | |
| CR20160309A (es) | Inhibidores de serina/treonina cinasa | |
| SA515361092B1 (ar) | تركيبات راسكادوتريل الدهنية | |
| EP2977388A4 (en) | COPOLYMER RUBBER WITH NITRILE GROUP, NETWORKABLE RUBBER COMPOSITION AND RUBBER-LINKED PRODUCT | |
| IL243995B (en) | Sustained release preparations made of hyaluronic acid, and their medical uses | |
| MX2016006335A (es) | Composicion suavizante de telas. | |
| WO2013190274A3 (en) | Biodegradable compositions | |
| MX359713B (es) | Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas. |